Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1707 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
NCT06199037Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Feb 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1707 in Alzheimer's disease (AD), sponsored by Hengrui Therapeutics. Started Feb 2024; status: terminated.
02
Drugs
SHR-1707
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06199037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199037.